Riskpilot← Back to searchSign inGet full accessHoivafarma Oy
OYActiveY-tunnus 2687199-8Vuokaari 2Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20150 employees
Revenue 2025
EUR 661K
-2% vs 2024
EBITDA margin
31.8%
+5% vs 2024
Equity ratio
86.4%
Financial strength
Net profit 2025
EUR 149K
-6% vs 2024
| Revenue | EUR 661K | -2% |
| EBITDA | EUR 210K | +5% |
| Net profit | EUR 149K | -6% |
| Total assets | EUR 1,5M | +9% |
| Equity | EUR 1,3M | +4% |
| Employees | 0 | — |
Legal name
Hoivafarma Oy
Y-tunnus number
2687199-8
Legal form
Osakeyhtiö
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
20. huhtikuuta 2015
Share capital
EUR 2 500
Employees
0
VAT registered
No
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin
Company purpose
Yhtiön toimialana on lääketieteellisten ja terveydenhoitoon liittyvien tuotteiden ja tarvikkeiden, kemikalio-, rohdos- ja luontaistuotteiden ja kosmetiikan vähittäis- ja tukkumyynti, tuonti, vienti ja valmistus ja lisäksi työvoiman sekä koneiden, laitteiden, kalusteiden, asuin- ja liikekiinteistöjen sekä huoneistojen vuokraus. Yhtiön toimialaan kuuluu myös lääke- ja apteekkialaan liittyvä konsultointi, tuotekehitys ja markkinointipalvelujen myynti. Yhtiö voi myös omistaa ja hallita arvopapereita, kiinteää ja irtainta omaisuutta, ostaa ja myydä arvopapereita, ostaa ja myydä asunto- ja kiinteistöyhtiön osakkeita sekä asuin- ja liikekiinteistöjä.
Address
Vuokaari 2
Phone
+3580505420675
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 791 | 796 | 806 | 817 | 921 | −796 | 678 | 661 |
| Staff expenses | 0 | −0 | −0 | −0 | −0 | 0 | −0 | −0 |
| EBITDA | 222 | 226 | 224 | 224 | 208 | 356 | 200 | 210 |
| Depreciation & amort. | −12 | −9 | −7 | −5 | −4 | −3 | −3 | −42 |
| EBIT | 211 | 217 | 218 | 220 | 204 | 353 | 2 782 | 168 |
| Net financials | −0 | 0 | −1 | −3 | −3 | −0 | 5 | 15 |
| Profit before tax | 211 | 218 | 217 | 217 | 201 | 353 | 202 | 183 |
| Tax | 42 | 44 | 43 | 43 | 42 | 67 | 43 | 33 |
| Net profit | 168 | 174 | 173 | 173 | 159 | 286 | 160 | 149 |
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total assets | 625 | 723 | 906 | 1 319 | 1 324 | 1 530 | 1 387 | 1 511 |
| Equity | 527 | 659 | 780 | 891 | 978 | 1 186 | 1 251 | 1 306 |
| Long-term debt | — | — | — | 225 | 75 | 0 | 0 | 0 |
| Short-term debt | 98 | 63 | 126 | 203 | 271 | 343 | 341 | 205 |
| Total debt | 98 | 63 | 126 | 428 | 346 | 343 | 341 | 205 |
EBITDA margin
31.8%
This company
15.8%
Market median
+101% vs market
20182025
Equity ratio
86.4%
This company
38.2%
Market median
+126% vs market
20182025
Return on equity
11.5%
This company
18.4%
Market median
+37% vs market
20182025
Net profit margin
22.6%
This company
8.1%
Market median
+179% vs market
20182025
Asset turnover
0.44×
This company
1.12×
Market median
-61% vs market
20182025
Debt / equity
0.16×
This company
0.62×
Market median
+74% vs market
20182025
- Annual report 2025Filed via PRH / YTJ · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via PRH / YTJ · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via PRH / YTJ · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via PRH / YTJ · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via PRH / YTJ · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via PRH / YTJ · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via PRH / YTJ · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via PRH / YTJ · Period 2018-01-01 – 2018-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AG Deputy auditor | Deputy auditor | 2015 | — | — |
MM Deputy auditor | Deputy auditor | 2025 | — | — |
CR | Audit | 2015 | — | — |
SR | Audit | 2025 | — | — |
EL Deputy Member | Deputy Member | 2015 | — | — |
RH Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Hoivafarma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Anders Gabriel Björk | Deputy auditor | 0 companies |
| Minna Marianne Peräkorpi | Deputy auditor | 0 companies |
| Christian Richard Räihä | Audit | 0 companies |
| Stefan Rolf Axel Wiklund | Audit | 0 companies |
| Emma Liisa Levijärvi | Deputy Member | 0 companies |
| Ritva Helena Kervinen | Chief Executive Officer | 0 companies |